GH Research (GHRS) Exchange Rate Effect (2020 - 2025)
GH Research (GHRS) posted quarterly Exchange Rate Effect of $155000.0 for Q4 2025, up 264.89% year-over-year from $42478.1 in Q4 2024, and up 160.78% quarter-over-quarter from -$255000.0 in Q3 2025.
GH Research (GHRS) Exchange Rate Effect (2020 - 2025) Analysis & Trends
GH Research's Exchange Rate Effect history runs 6 years deep, the most recent figure standing at $155000.0 for Q4 2025.
- In Q4 2025, Exchange Rate Effect rose 264.89% year-over-year to $155000.0; the TTM figure through Dec 2025 stood at $3.2 million (up 1922.29% YoY), while the FY2025 annual figure was $3.2 million, up 1922.29% from the prior year.
- Exchange Rate Effect for Q4 2025 stood at $155000.0, up from -$255000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $3.2 million in Q2 2025, with the low at -$378000.0 in Q3 2022.
- The 5-year median for Exchange Rate Effect is -$18000.0 (2021), against an average of $150300.0.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect tumbled 2420.0% in 2022, then jumped 9655.88% in 2025.
- GH Research's Exchange Rate Effect stood at -$21000.0 in 2021, then soared by 2585.71% to $522000.0 in 2022, then tumbled by 74.9% to $131000.0 in 2023, then tumbled by 171.76% to -$94000.0 in 2024, then jumped by 264.89% to $155000.0 in 2025.
- Business Quant data shows GHRS's Exchange Rate Effect at $155000.0 in Q4 2025, -$255000.0 in Q3 2025, and $3.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 155,000.00 |
| Dec 31, 2025 | 155,000.00 |
| Sep 30, 2025 | -255,000.00 |
| Sep 30, 2025 | -255,000.00 |
| Jun 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | 3.25 Mn |
| Mar 31, 2025 | 40,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | -52,000.00 |
| Sep 30, 2023 | -52,000.00 |